Section Arrow
ABVX.NASDAQ
- Abivax SA
Quotes are at least 15-min delayed:2024/04/29 15:37 EDT
Last
 15.79
+0.01 (+0.06%)
Day High 
16.63 
Prev. Close
15.78 
1-M High
16.59 
Volume 
87.13K 
Bid
15.78
Ask
15.89
Day Low
15.6238 
Open
16.63 
1-M Low
13.6 
Market Cap 
992.84M 
Currency USD 
P/E -- 
%Yield
10-SMA 15.37 
20-SMA 15.09 
50-SMA 14.4 
52-W High 17.02 
52-W Low 7.995 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.43/-2.88
Enterprise Value
1.04B
Balance Sheet
Book Value Per Share
3.33
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
4.62M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
DNAGinkgo Bioworks Holdings0.9932+0.1331+15.47%-- 
JAGXJaguar Health0.2007+0.0207+11.50%-- 
IBRXImmunityBio8.71+1.36+18.50%-- 
GERNGeron Corp4.175+0.385+10.16%-- 
XFORX4 Pharmaceuticals1.1506-0.0144-1.24%-- 
Quotes are at least 15-min delayed:2024/04/29 15:37 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Theyare evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.